Deferasirox

Deferasirox belongs to iron chelators family. FDA approved it in November 2005. Deferasirox is the first drug approved in US for oral administration in the treatment of iron overload for anemia for the patients receiving blood transfusions. Iron chelators facilitate the removal of iron by making a bound with iron.

Brands
DASIROX DASIROX ASUNRA ASUNRA ODEROX ODEROX
Adult Dose
Neonatal
Paedriatic
Characteristics
It belongs to Chlelating agent pharmacological group on the basis of mechanism of action. The Molecular Weight of Deferasirox is 373.36.
Contraindications
Deferasirox
Effects
The symptomatic adverse reactions produced by Deferasirox are more or less tolerable and if they become severe, they can be treated symptomatically, these include Nausea, Vomiting, Diarrhea, Skin rash, Stomach pain.
Indications
Deferasirox is primarily indicated in conditions like Blood transfusion, Chronic iron overload.
Interactions
No data regarding the interactions of Deferasirox was found.
Interfrence
Risks
If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Warnings
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.